Skip to main content

Just Say Yes to the Drugs

The group's earnings look great and the trader is now thrilled with his buys on Tuesday.
  • Author:
  • Publish date:

Looks like I picked the wrong day to feel like an idiot. Our sales yesterday are bringing smiles to our faces and our buys -- the drugs -- are looking stellar. We are elated with the drug earnings, and we get the sense that the market wants liquidity and safety again. For today, drugs are going higher.

We are sneaking bids in on our fave tech names, everything from

Intel

(INTC) - Get Intel Corporation Report

to

Microsoft

TheStreet Recommends

(MSFT) - Get Microsoft Corporation Report

to rebuild those positions. We are not touching Buzz Gould-type names though, as they are

too hard for us to maneuver in.

Is this market

hard enough for you yet?

James J. Cramer is manager of a hedge fund and co-founder of TheStreet.com. At time of publication, his fund was long Intel and Microsoft. His fund often buys and sells securities that are the subject of his columns, both before and after the columns are published, and the positions that his fund takes may change at any time. Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. Cramer's writings provide insights into the dynamics of money management and are not a solicitation for transactions. While he cannot provide investment advice or recommendations, he invites you to comment on his column at

jjcletters@thestreet.com.